Legal & General Group Plc decreased its position in Albany Molecular Research, Inc. (NASDAQ:AMRI) by 0.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 37,076 shares of the biotechnology company’s stock after selling 80 shares during the period. Legal & General Group Plc’s holdings in Albany Molecular Research were worth $520,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Royce & Associates LP boosted its stake in shares of Albany Molecular Research by 17.6% in the first quarter. Royce & Associates LP now owns 1,518,276 shares of the biotechnology company’s stock worth $21,301,000 after buying an additional 227,365 shares during the last quarter. State Street Corp boosted its stake in shares of Albany Molecular Research by 7.2% in the fourth quarter. State Street Corp now owns 512,819 shares of the biotechnology company’s stock worth $9,623,000 after buying an additional 34,448 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of Albany Molecular Research by 5.1% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 491,312 shares of the biotechnology company’s stock worth $6,893,000 after buying an additional 23,833 shares during the period. Bank of New York Mellon Corp raised its position in shares of Albany Molecular Research by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 461,114 shares of the biotechnology company’s stock worth $6,470,000 after buying an additional 26,039 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of Albany Molecular Research by 3.6% in the first quarter. Principal Financial Group Inc. now owns 170,686 shares of the biotechnology company’s stock worth $2,395,000 after buying an additional 5,960 shares during the period. 76.73% of the stock is currently owned by institutional investors and hedge funds.

Shares of Albany Molecular Research, Inc. (AMRI) traded up 0.14% on Friday, reaching $21.72. The company’s stock had a trading volume of 736,537 shares. The stock’s market capitalization is $903.64 million. Albany Molecular Research, Inc. has a 1-year low of $13.01 and a 1-year high of $22.17. The company has a 50 day moving average of $21.68 and a 200 day moving average of $17.85.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.01. The company had revenue of $163.80 million for the quarter, compared to analyst estimates of $161.43 million. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. Albany Molecular Research’s revenue was up 55.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.07 earnings per share. Equities research analysts expect that Albany Molecular Research, Inc. will post $1.13 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Legal & General Group Plc Has $520,000 Stake in Albany Molecular Research, Inc. (AMRI)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/05/legal-general-group-plc-has-520000-stake-in-albany-molecular-research-inc-amri.html.

A number of research analysts have recently issued reports on AMRI shares. William Blair reiterated an “outperform” rating on shares of Albany Molecular Research in a research report on Tuesday, May 23rd. Morgan Stanley lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 target price on the stock. in a research report on Thursday, May 11th. They noted that the move was a valuation call. BidaskClub lowered Albany Molecular Research from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. First Analysis lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. Finally, J P Morgan Chase & Co lowered Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. Albany Molecular Research currently has an average rating of “Hold” and an average price target of $18.00.

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.